Chimeric autoantibody receptor T cells specifically eliminate Graves' Disease autoreactive B cells.

ABSTRACT:

Introduction

Chimeric antigen receptor (CAR) T cells have recently become an important treatment for hematological cancers by efficiently eliminating B cells. B cell depleting CAR T cells are also in clinical trials for their use in treating severe autoimmune diseases and have shown promise in patients who have exhausted other treatment options; however, they do result in immunosuppression due to B cell depletion. Specifically eliminating the disease-causing B cells while leaving the healthy B cells untouched could address this limitation.

Methods

A chimeric autoantibody receptor (CAAR) has an autoantigen as the binding domain of the CAR T cell and could allow for specific targeting of autoreactive B cell populations. In Graves' Disease (GD), pathogenesis is centered around

SUBMITTER: Cheever A 

PROVIDER: S-EPMC12011768 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature